Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
NEW YORK, Feb. 16, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased HeartWare International, Inc. (Nasdaq:HTWR) securities between June 10, 2014 and January 11, 2016.
Click here to learn about the case: http://docs.wongesq.com/HTWR-Info-Request-Form-1018. There is no cost or obligation to you.
The complaint alleges that during the Class Period, HeartWare and certain of its senior executives made false and misleading statements and omitted material information. In particular, it is alleged that after the U.S. Food and Drug Administration issued a Warning Letter identifying numerous manufacturing and other regulatory failures at the Company’s sole manufacturing facility, Defendants falsely assured investors that the Company had addressed those problems, and that these concerns therefore posed no risk to the clinical trials or timely approval of MVAD, a pump that HeartWare is developing.
Following a series of disclosures regarding adverse effects in certain clinical trial patients, shares of HeartWare have declined from a close of $87.73 per share on June 25, 2014, to a close of just $34.50 per share on January 22, 2016.
If you suffered a loss in HeartWare you have until March 22, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/HTWR-Info-Request-Form-1018.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigation involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
